Greg Harrison
Stock Analyst at Scotiabank
(1.84)
# 2,928
Out of 4,793 analysts
79
Total ratings
31.75%
Success rate
-8.9%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $30 → $31 | $19.97 | +55.23% | 3 | Apr 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $14.99 | +106.80% | 9 | Apr 1, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $338 → $342 | $235.74 | +45.08% | 5 | Mar 31, 2025 | |
| LQDA Liquidia | Maintains: Sector Outperform | $30 → $34 | $12.90 | +163.57% | 5 | Mar 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Sector Outperform | $40 | $15.27 | +161.95% | 5 | Mar 10, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sector Outperform | $51 → $52 | $5.12 | +915.63% | 4 | Mar 3, 2025 | |
| IRON Disc Medicine | Maintains: Sector Outperform | $73 → $75 | $41.22 | +81.95% | 4 | Mar 3, 2025 | |
| GERN Geron | Maintains: Sector Outperform | $6 → $4 | $1.38 | +189.86% | 2 | Feb 27, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $49 → $52 | $31.37 | +65.76% | 5 | Feb 21, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $433 → $450 | $474.62 | -5.19% | 5 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $44 → $41 | $9.98 | +310.82% | 5 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $53 → $75 | $25.76 | +191.15% | 4 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $60 | $21.31 | +181.56% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $4.61 | +290.46% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $6.36 | +246.18% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $1.03 | +1,356.31% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $303 → $280 | $292.46 | -4.26% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $6.63 | +1,272.55% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $5.94 | +102.02% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.66 | +128.48% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $12.40 | +214.52% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $7.06 | -57.51% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $2.92 | +2,297.26% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $28.94 | -72.36% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $16.91 | +219.34% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 → $6 | $0.55 | +987.15% | 5 | Mar 14, 2022 |
Apellis Pharmaceuticals
Apr 2, 2025
Maintains: Sector Perform
Price Target: $30 → $31
Current: $19.97
Upside: +55.23%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $14.99
Upside: +106.80%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Sector Outperform
Price Target: $338 → $342
Current: $235.74
Upside: +45.08%
Liquidia
Mar 20, 2025
Maintains: Sector Outperform
Price Target: $30 → $34
Current: $12.90
Upside: +163.57%
Beam Therapeutics
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $15.27
Upside: +161.95%
Rocket Pharmaceuticals
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $51 → $52
Current: $5.12
Upside: +915.63%
Disc Medicine
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $41.22
Upside: +81.95%
Geron
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $6 → $4
Current: $1.38
Upside: +189.86%
BridgeBio Pharma
Feb 21, 2025
Maintains: Sector Outperform
Price Target: $49 → $52
Current: $31.37
Upside: +65.76%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Sector Perform
Price Target: $433 → $450
Current: $474.62
Upside: -5.19%
Jan 16, 2025
Maintains: Sector Outperform
Price Target: $44 → $41
Current: $9.98
Upside: +310.82%
Dec 9, 2024
Maintains: Sector Outperform
Price Target: $53 → $75
Current: $25.76
Upside: +191.15%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $60
Current: $21.31
Upside: +181.56%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $4.61
Upside: +290.46%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $6.36
Upside: +246.18%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $1.03
Upside: +1,356.31%
Aug 1, 2024
Maintains: Underperform
Price Target: $303 → $280
Current: $292.46
Upside: -4.26%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $6.63
Upside: +1,272.55%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $5.94
Upside: +102.02%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.66
Upside: +128.48%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $12.40
Upside: +214.52%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $7.06
Upside: -57.51%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $2.92
Upside: +2,297.26%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $28.94
Upside: -72.36%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $16.91
Upside: +219.34%
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $0.55
Upside: +987.15%